Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report) saw unusually-high trading volume on Monday. 798,287 shares changed hands during trading, an increase of 289% from the previous session’s volume of 205,006 shares. The stock last traded at $11.5650 and had previously closed at $11.60.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, the company currently has an average rating of “Hold”.
Get Our Latest Analysis on SSMXY
Sysmex Stock Performance
The company has a quick ratio of 2.53, a current ratio of 3.40 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average price of $11.90 and a 200 day moving average price of $10.11. The stock has a market cap of $7.19 billion, a PE ratio of 28.14 and a beta of 1.18.
Sysmex (OTCMKTS:SSMXY – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 8.01% and a net margin of 7.62%. The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Analysts expect that Sysmex Corporation ADR will post 0.41 earnings per share for the current year.
About Sysmex
Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes clinical laboratory instruments, reagents and related information systems. Its products are used by hospitals, diagnostic laboratories and other healthcare providers to support the analysis of blood, urine and other biological samples.
The company is best known for its hematology analyzers, which help laboratories evaluate blood cells and identify conditions such as anemia and leukemia.
Further Reading
- Five stocks we like better than Sysmex
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
